In December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) occurred in Wuhan, Hubei, which has been linked to the severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2). It is characterized by rapid human-to-human transmission from droplet contamination.^[@cld200010r1],[@cld200010r2]^ A report of 138 hospitalized patients from a single institution (Zhongnan Hospital of Wuhan University) indicated that hospital-acquired transmission accounted for 41.3% of these admitted patients, thus implicating the hospital environment as a source of spread of the virus.^[@cld200010r3]^ Patients with cancer are often recalled to the hospital for treatment and monitoring, and hence, they may be at risk of contracting COVID-19. Moreover, cancer treatments such as chemotherapy and radiotherapy are immunosuppressive. Here, we report the incidence and outcomes of SARS-CoV-2 infection in cancer patients who were treated at a tertiary cancer institution in Wuhan.

Methods {#H1-1-CLD200010}
=======

We reviewed the medical records, including demographic, clinical, and treatment data of 1524 patients with cancer who were admitted to the Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, from December 30, 2019, to February 17, 2020 (data cutoff date). COVID-19 pneumonia was diagnosed based on the updated COVID-19 Diagnostic Criteria, 5th Edition ([Supplement](#note-CLD200010-1-s){ref-type="supplementary-material"}). Outcomes of COVID-19 among patients with cancer were reported.

This retrospective study was approved by the Zhongnan Hospital of Wuhan University ethics committee (2020039). Waiver of informed consent was approved for the aggregated data; verbal informed consent was obtained from the living patients with COVID-19.

Results {#H1-2-CLD200010}
=======

We estimated the infection rate of SARS-CoV-2 in patients with cancer from our single institution at 0.79% (12 of 1524 patients; 95% CI, 0.3%-1.2%). This was higher than the cumulative incidence of all diagnosed COVID-19 cases that was reported in the city of Wuhan over the same time period (0.37%; 41 152 of 11 081 000 cases; data cutoff on February 17, 2020). Clinical details on the cancer diagnoses and treatment history are summarized in [Table 1](#cld200010t1){ref-type="table"}. The median age of infected patients was 66 years (range, 48 to 78 years); 8 of 12 patients (66.7%) were older than 60 years. Seven of 12 (58.3%) patients had non--small cell lung carcinoma (NSCLC). Five (41.7%) were being treated with either chemotherapy with or without immunotherapy (n = 3) or radiotherapy (n = 2). Three patients (25.0%) developed SARS; 1 patient required intensive-level care. As of March 10, 2020, 6 patients (50.0%) had been discharged, whereas 3 deaths (25.0%) were recorded.

###### Clinical Characteristics and Outcomes of Patients With Cancer With SARS-CoV-2 Infection

  Patient No.   Sex      PS   Cancer diagnosis    Phase of cancer treatment                                                                                                               Time between onset of symptoms and diagnosis, d   Fever   Dyspnea   Cough   CT diagnosis    SARS-COV-2 RT-PCR assay   Severe COVID-19   Hospitalization status   Duration of hospitalization, d   Survival status[^a^](#cld200010t1n1){ref-type="table-fn"}
  ------------- -------- ---- ------------------- --------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ------- --------- ------- --------------- ------------------------- ----------------- ------------------------ -------------------------------- -----------------------------------------------------------
  1             Male     1    NSCLC               Concurrent EGFR TKI (osimertinib \[80 mg/d\]) with concurrent thoracic radiotherapy (27 Gy in 9 fr)                                     8                                                 Yes     No        No      Positive        Positive                  No                Discharged               19                               Alive
  2             Male     1    NSCLC               W5 of chemoradiotherapy (chemotherapy regime: pemetrexed \[500 mg/m^2^\], cisplatin \[75 mg/m^2^\] q3W; radiotherapy (54 Gy in 27 fr)   1                                                 Yes     Yes       Yes     Positive        Negative                  Yes               Discharged               31                               Dead
  3             Female   3    NSCLC               Admitted for pleural effusion; best supportive care                                                                                     0                                                 Yes     Yes       Yes     Positive        Negative                  No                Discharged               13                               Alive
  4             Male     1    NSCLC               Follow-up at 2 y postchemoradiotherapy; no evidence of disease relapse                                                                  0                                                 Yes     Yes       Yes     Positive        Negative                  Yes               Discharged               2                                Dead
  5             Male     1    NSCLC               After first cycle (docetaxel, \[75 mg/m^2^\], cisplatin \[75 mg/m^2^\], sintilimab, \[200 mg\])                                         0                                                 Yes     No        No      Positive        Negative                  No                Discharged               12                               Alive
  6             Male     1    NSCLC               After third cycle (pemetrexed \[500 mg/m^2^\], carboplatin \[AUC5\], pembrolizumab \[200 mg\])                                          0                                                 Yes     No        No      Positive        Negative                  No                Discharged               32                               Alive
  7             Male     1    NSCLC               Surgery (April 23, 2019), after 4 cycles adjuvant chemotherapy (docetaxel \[75 mg/m^2^\], cisplatin \[75 mg/m^2^\])                     0                                                 Yes     No        No      Positive        Negative                  No                Discharged               8                                Alive
  8             Male     2    Rectal cancer       Best supportive care                                                                                                                    0                                                 Yes     No        No      Positive        Negative                  No                Inpatient                48                               Alive
  9             Male     1    Colon cancer        Newly diagnosed; treatment yet to commence                                                                                              23                                                Yes     No        No      Negative        Positive                  No                Inpatient                26                               Alive
  10            Male     3    Pancreatic cancer   Best supportive care                                                                                                                    0                                                 Yes     No        No      Positive        Negative                  Yes               Discharged               1                                Dead
  11            Female   1    Breast cancer       Adjuvant radiotherapy (42 Gy in 21 fr)                                                                                                  2                                                 Yes     No        No      Positive        Positive                  No                Discharged               27                               Alive
  12            Male     2    Urothelial cancer   Best supportive care                                                                                                                    6                                                 Yes     No        No      Not performed   Positive                  No                Inpatient                22                               Alive

Abbreviations: AUC5, area under the curve 5; COVID-19, 2019 novel coronavirus disease; CT, computed tomography; EGFR, epidermal growth factor receptor; fr, radiotherapy fraction; NSCLC, non--small cell lung cancer; PS, performance status; q3w, every 3 weeks; RT-PCR, real-time quantitative polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TKI, tyrosine kinase inhibitor.

Survival and hospitalization status were updated as of March 10, 2020.

We also interrogated the association of SARS-Cov-2 infection with age and concurrent NSCLC diagnosis. Of the 1524 patients with cancer who were screened, 228 had NSCLC. We found that patients with NSCLC older than 60 years had a higher incidence of COVID-19 than those aged 60 years or younger (4.3% vs 1.8%) ([Table 2](#cld200010t2){ref-type="table"}).

###### COVID-19 Pneumonia in Patients With NSCLC of Different Age Groups Treated at the Zhongnan Hospital of Wuhan University

  Age, y   No. (%)      
  -------- ------------ ----------------
  ≤60      111 (48.7)   2 of 111(1.8)
  \>60     117 (51.3)   5 of 117 (4.3)

Abbreviations: COVID-19, 2019 novel coronavirus disease; NSCLC, non--small cell lung cancer.

Discussion {#H1-3-CLD200010}
==========

It is hypothesized that patients with cancer may be susceptible to an infection during a viral epidemic owing to their immunocompromised status.^[@cld200010r4]^ This study highlights the following observations: patients with cancer from the epicenter of a viral epidemic harbored a higher risk of SARS-CoV-2 infection (OR, 2.31; 95% CI, 1.89-3.02) compared with the community. However, fewer than half of these infected patients were undergoing active treatment for their cancers. Next, we observed that older patients (\>60 years) and patients with NSCLC may be at risk of COVID-19. Nonetheless, a population study of 1099 patients with COVID-19 did not indicate that age was associated with susceptibility to infection.^[@cld200010r5]^ A larger sample size in patients with cancer will resolve these potential associations. Finally, our findings imply that hospital admission and recurrent hospital visits are potential risk factors for SARS-CoV-2 infection.

We propose that aggressive measures be undertaken to reduce frequency of hospital visits of patients with cancer during a viral epidemic going forward. For patients who require treatment, proper isolation protocols must be in place to mitigate the risk of SARS-CoV-2 infection.
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